Mach7 Technologies (M7T) investor relations material

Executive summary

• Leadership executed a strategic reset, emphasizing operational discipline, cost reduction, and a startup mindset, while leveraging an enterprise-grade foundation.

• Achieved positive operating cash flow of A$1.2M in Q3 FY26, a significant improvement over Q2 FY26, driven by lower staff and corporate costs.

• Commercial and cultural transformation unified teams, strengthened CRM, pricing, and pipeline management, and prioritized customer focus and rapid iteration.

• Early traction in digital pathology and Flamingo modules, with first Flamingo customer signed and pipeline expansion underway.

• Expanded partner ecosystem, including new regional resellers, multi-cloud alliances, and international reach, supporting revenue growth.

Financial highlights

• Annual Recurring Revenue (ARR) run rate reached A$22.8M at 31 March 2026, up 2% in constant currency from 31 December 2025.

• Contracted ARR (CARR) was A$25.8M, up A$0.3M from 31 December 2025, including A$3M in backlog.

• Q3 FY26 sales orders totaled A$6.0M (TCV), up 25% year-over-year, with 89% representing ARR-type sales.

• Operating cash flow was positive at A$1.2M, with cash receipts of A$8.1M, up 2.7% sequentially.

• Quarter-end cash balance was A$19.2M, up from A$18.2M at 31 December 2025, with no debt.

Outlook and guidance

• FY26 is an operational reset year, with revenue expected to be approximately 15% below FY25 due to delayed capital deal conversion and reduced services revenue, especially in the Middle East.

• Operating expenses for FY26 are forecast to be about 10% lower than FY25, reflecting improved cost control.

• Services revenue is expected to recover as new contracts and expanded offerings come online.

• Emphasis is shifting toward recurring revenue, with a solid and growing pipeline expected to drive future CARR and revenue growth.

• Positioned for future operating leverage as execution and conversion progress into FY27.